Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida.
Department of Otolaryngology, University of Florida College of Medicine, Gainesville, Florida.
Head Neck. 2019 Jul;41(7):2107-2110. doi: 10.1002/hed.25664. Epub 2019 Feb 19.
To update our experience treating benign head-and-neck paragangliomas (PGs) with radiotherapy (RT).
A total of 149 patients with 176 PGs received curative-intent RT; 126 received RT to 1 PG and 23 to 2 or more PGs. The most common dose fractionation schedule was 45 Gy/25 once-daily fractions/5 weeks which was used to treat 147 PGs (83.5%) in 123 patients (82.6%). Patients were followed with physical examination and CT/MRI. The median follow-up for all patients was 10.6 years (range, 0.2-50.4 years); the median follow-up for surviving patients was 11.1 years (range, 0.2-50.4).
The 5-year, 10-year, and 15-year outcomes were: local control, 99%, 96%, and 95%; distant metastasis-free survival, 99%, 99%, and 99%; cause-specific survival, 98%, 98%, and 98%; and overall survival, 90%, 75%, and 64%, respectively. No patient developed a moderate or severe complication, or a radiation-induced second tumor or malignant transformation of the benign PG.
RT is an effective treatment for head-and-neck PGs with a low risk of complications.
更新我们使用放射治疗（RT）治疗良性头颈部副神经节瘤（PGs）的经验。
共有 149 例 176 个 PG 患者接受了根治性 RT；126 例患者接受了 1 个 PG 的 RT，23 例患者接受了 2 个或更多 PG 的 RT。最常见的剂量分割方案是 45 Gy/25 次/5 周，123 例患者（82.6%）中的 147 个 PG（83.5%）采用了这种方案。患者接受了体格检查和 CT/MRI 随访。所有患者的中位随访时间为 10.6 年（范围：0.2-50.4 年）；存活患者的中位随访时间为 11.1 年（范围：0.2-50.4 年）。
5 年、10 年和 15 年的局部控制率分别为：99%、96%和 95%；远处无转移生存率分别为：99%、99%和 99%；特异性生存率分别为：98%、98%和 98%；总生存率分别为：90%、75%和 64%。没有患者发生中度或重度并发症，也没有发生放射性第二肿瘤或良性 PG 的恶性转化。
RT 是治疗头颈部 PG 的有效方法，并发症风险低。
